华东医药(000963) - 2014 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2014 was ¥4,503,274,601.33, representing a 13.03% increase compared to ¥3,984,259,585.94 in the same period last year[8] - The net profit attributable to shareholders was ¥201,737,994.08, up 26.25% from ¥159,798,265.44 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥202,705,658.20, reflecting a 30.06% increase from ¥155,859,366.26 in the previous year[8] - The basic earnings per share increased to ¥0.4648, a rise of 26.25% compared to ¥0.3681 in the same period last year[8] Assets and Shareholder Equity - The total assets at the end of the reporting period were ¥8,876,960,139.78, marking a 15.68% increase from ¥7,673,413,590.03 at the end of the previous year[8] - The net assets attributable to shareholders reached ¥2,775,057,541.58, which is a 7.84% increase from ¥2,573,319,547.50 at the end of the previous year[8] Cash Flow and Financial Ratios - The company reported a negative net cash flow from operating activities of ¥464,830,344.81, worsening from a negative cash flow of ¥382,600,988.68 in the same period last year[8] - The weighted average return on equity was 7.54%, slightly down from 7.69% in the previous year[8] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,608[11] - The largest shareholder, China Yuanda Group Co., Ltd., held 35.5% of the shares, amounting to 154,107,432 shares, which are currently frozen[11] Receivables and Payables - Accounts receivable increased by 32.09% to ¥3,520,902,103.17, primarily due to increased operating revenue[17] - Other receivables rose by 112.50% to ¥70,364,509.56, mainly due to an increase in temporary payments[17] - Payables increased by 38.22% to ¥269,967,021.93, mainly due to an increase in the use of notes for settlement[17] - Other payables rose by 52.58% to ¥362,533,555.69, mainly due to an increase in temporary receipts and payables[17] Borrowings and Dividends - Short-term borrowings increased by 43.91% to ¥2,259,371,927.56, primarily due to new borrowings obtained by the company[17] - Dividend payables surged by 55,748.92% to ¥125,224,219.60, primarily due to increased dividends payable to minority shareholders by subsidiaries[17] Taxation and Operating Expenses - Operating tax and additional charges increased by 32.35% to ¥23,344,497.65, primarily due to increased tax liabilities from subsidiaries[17] - The company reported a 54.34% increase in paid taxes to ¥318,955,204.87, primarily due to increased VAT payments[17] - Other operating expenses increased by 31.07% to ¥477,414,477.51, mainly due to higher cash expenses related to operations[17] - Investment income decreased by 63.17% to ¥480,300.00, mainly due to a decline in profits from associated companies[17]